Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $265.00 Price Target at Wells Fargo & Company

Key Points

• Wells Fargo raised its price target on Jazz Pharmaceuticals to $265 (from $250) and maintained an "overweight" rating, implying roughly a 17% upside from the prior close.
• Jazz reported a strong quarterly EPS of $6.34 and ~19% year‑over‑year revenue growth, and its HER2 candidate zanidatamab received a Priority Review with a PDUFA date of Aug 25, 2026, creating a near‑term binary for the stock.
• Insiders sold about 74,015 shares (~$14.18M) in the quarter while institutions own roughly 89% of the stock; shares traded at $225.89 (near a 1‑year high of $230.40) and the market cap is about $14.17B.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price objective hoisted by equities researchers at Wells Fargo & Company from $250.00 to $265.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the specialty pharmaceutical company's stock. Wells Fargo & Company's price objective indicates a potential upside of 17.32% from the company's previous close.

Other equities analysts also recently issued research reports about the company. Bank of America raised their target price on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Weiss Ratings restated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a research report on Friday, March 27th. TD Cowen restated a "buy" rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Barclays set a $234.00 target price on Jazz Pharmaceuticals in a research report on Wednesday. Finally, Leerink Partners raised their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $221.33.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $13.63 during trading on Wednesday, hitting $225.89. 277,431 shares of the stock were exchanged, compared to its average volume of 992,150. Jazz Pharmaceuticals has a 1-year low of $97.50 and a 1-year high of $230.40. The company has a market capitalization of $14.17 billion, a price-to-earnings ratio of -37.86, a price-to-earnings-growth ratio of 0.36 and a beta of 0.27. The company's fifty day simple moving average is $190.45 and its 200-day simple moving average is $171.65. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company had revenue of $1.07 billion for the quarter. Sell-side analysts expect that Jazz Pharmaceuticals will post 20.51 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Norbert G. Riedel sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares of the company's stock, valued at approximately $1,348,608. This trade represents a 32.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the sale, the senior vice president directly owned 28,728 shares of the company's stock, valued at $5,587,308.72. This trade represents a 15.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in JAZZ. Farther Finance Advisors LLC grew its stake in Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company's stock valued at $35,000 after acquiring an additional 234 shares during the period. Hilltop National Bank bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $36,000. LRI Investments LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $38,000. Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $40,000. Finally, Quent Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $44,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Large EPS beat - Jazz reported $6.34 EPS vs. consensus ~$4.67, a sizeable upside that drove investor enthusiasm for profitability and cash-generation potential. Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Pipeline catalyst — zanidatamab (HER2+ 1L GEA) received Priority Review with a PDUFA date of Aug 25, 2026, creating a clear near-term binary that could materially affect long-term revenues if approved. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Positive Sentiment: Commercial growth — management highlighted ~19% YoY revenue growth and product-level strength (Xywav and Epidiolex growth; net patient adds), supporting the view that core franchises are expanding. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: Guidance reaffirmed — the company reiterated 2026 revenue and expense guidance, which reduces uncertainty but leaves investors waiting for full-year detail and cadence. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: More detail available — the earnings call transcript and slide deck provide management color on growth drivers and cost assumptions for 2026; useful for modeling but not an immediate directional news item. Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Top-line slightly missed Street revenue consensus (reported ~$975M vs. ~$978M estimate), which tempers the beat and suggests some near-term sales variability. Jazz Pharmaceuticals Q1 Results Summary
• Negative Sentiment: GAAP profitability and margins — the company still reported a negative net margin and modest ROE; investors should watch how one-time items, R&D and SG&A trends affect sustained profitability. Jazz Pharmaceuticals Q1 Results Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.